Cucurbitacin I exerts its anticancer effects by inducing cell cycle arrest via the KAT2a-ube2C/E2F1 pathway and inhibiting HepG2-induced macrophage M2 polarization
Biochemical and Biophysical Research Communications · 2024
DOI: 10.1016/j.bbrc.2024.150508 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2024. Verfasst von Xiaocheng Gong und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Biology and Biological Engineering, South China University of Technology, Guangzhou, PR China. Hauptthemen laut MEDLINE: Cell Cycle Checkpoints, Ubiquitin-Conjugating Enzymes, E2F1 Transcription Factor. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 84 Literaturangaben.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is one of the most common malignancies globally, particularly prevalent in China, where it accounts for nearly half of the world's new cases and deaths each year, but has limited therapeutic options. This study systematically investigated the impact of cucurbitacin I on HCC cell lines including SK-Hep-1, Huh-7, and HepG2. The results revealed that cucurbitacin I not only inhibited cell proliferation, cell migration and colony formation, but also induced apoptosis in HCC cells. The apoptotic induction was accompanied by a decrease in the expression of the anti-apoptotic factor B-cell lymphoma 2 (Bcl2), and an elevation in the expression levels of pro-apoptotic factors, including tumor protein p53 (P53), bcl2 associated X-apoptosis regulator (Bax), and caspase3 (Cas3). Additionally, cucurbitacin I caused cell cycle arrest by modulating the lysine acetyltransferase 2A (KAT2A)-E2F transcription factor 1 (E2F1)/Ubiquitin-conjugating enzyme E2 C (UBE2C) signaling axis. In terms of regulation on tumor microenvironment, cucurbitacin I was demonstrated the ability to inhibit HCC cell-induced M2 polarization of macrophages. This comprehensive study unveils the multifaceted anti-cancer mechanisms of cucurbitacin I, providing robust support for its potential application in the treatment of HCC, offering new avenues for the future development of HCC treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biology and Biological Engineering, South China University of Technology, Guangzhou, PR China.
- School of Biology and Biological Engineering, South China University of Technology, Guangzhou, PR China. Electronic address: hldu@scut.edu.cn.
Zitieren
APA
Gong, X., Liu, Y., Liang, K., Chen, Z., Ding, K., Qiu, L., Wei, J., & Du, H. (2024). Cucurbitacin I exerts its anticancer effects by inducing cell cycle arrest via the KAT2a-ube2C/E2F1 pathway and inhibiting HepG2-induced macrophage M2 polarization. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2024.150508
Vancouver
Gong X, Liu Y, Liang K, Chen Z, Ding K, Qiu L, et al. Cucurbitacin I exerts its anticancer effects by inducing cell cycle arrest via the KAT2a-ube2C/E2F1 pathway and inhibiting HepG2-induced macrophage M2 polarization. Biochemical and Biophysical Research Communications. 2024. doi:10.1016/j.bbrc.2024.150508
BibTeX
@article{Gong2024,
author = {Gong, Xiaocheng and Liu, Yunfei and Liang, Keying and Chen, Zixi and Ding, Ke and Qiu, Li and Wei, Jinfen and Du, Hongli},
title = {Cucurbitacin I exerts its anticancer effects by inducing cell cycle arrest via the KAT2a-ube2C/E2F1 pathway and inhibiting HepG2-induced macrophage M2 polarization},
journal = {Biochemical and Biophysical Research Communications},
year = {2024},
doi = {10.1016/j.bbrc.2024.150508}
}
EUVIMED